{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:46:10Z","timestamp":1788547570434,"version":"build-2803163510"},"reference-count":41,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,10,16]],"date-time":"2012-10-16T00:00:00Z","timestamp":1350345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Geriat Psychiatry"],"published-print":{"date-parts":[[2013,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of the study was to evaluate once\u2010daily extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder (GAD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An 11\u2010week (9\u2010week treatment; 2\u2010week posttreatment), randomized, double\u2010blind, placebo\u2010controlled study (D1448C00015) of flexibly\u2010dosed quetiapine XR (50\u2013300\u2009mg\/day) or placebo conducted at 47 sites (Estonia, Poland, Russia, Ukraine, and USA) between September 2006 and April 2008. Patients (\u226566\u2009years) with DSM\u2010IV diagnosis of GAD, Hamilton Anxiety Rating Scale (HAM\u2010A) total score of \u226520 with item 1 (anxious mood) and 2 (tension) scores of \u22652, Clinical Global Impressions\u2013Severity of Illness (CGI\u2010S) score of \u22654, and Montgomery \u00c5sberg Depression Rating Scale (MADRS) total score of \u226416 were eligible for inclusion. Primary endpoint: week 9 change from randomization in HAM\u2010A total score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients were randomized to quetiapine XR (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009223) or placebo (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009227). At week 9, quetiapine XR significantly reduced HAM\u2010A total score versus placebo (least squares mean \u221214.97 versus \u22127.21;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001); symptom improvement with quetiapine XR versus placebo was significant at week 1 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). At week 9, quetiapine XR demonstrated significant benefits over placebo for HAM\u2010A response and remission rates, HAM\u2010A psychic and somatic cluster, MADRS total, CGI\u2010S, Pittsburgh Sleep Quality Index global, pain visual analog scale, and Quality of Life, Enjoyment and Satisfaction Questionnaire short form % maximum total scores and Clinical Global Impressions\u2013Improvement (% patients with a score of 1\/2) (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Adverse events (&gt;5% in either treatment group) included somnolence, dry mouth, dizziness, headache, and nausea.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Quetiapine XR (50\u2013300\u2009mg\/day) monotherapy is effective in the short term in improving symptoms of anxiety in older patients with GAD, with symptom improvement seen as early as week 1. Tolerability findings were generally consistent with the known profile of quetiapine. Copyright \u00a9 2012 John Wiley &amp; Sons, Ltd.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/gps.3867","type":"journal-article","created":{"date-parts":[[2012,10,16]],"date-time":"2012-10-16T02:26:13Z","timestamp":1350354373000},"page":"615-625","source":"Crossref","is-referenced-by-count":39,"title":["Double\u2010blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder"],"prefix":"10.1002","volume":"28","author":[{"given":"Irina","family":"Mezhebovsky","sequence":"first","affiliation":[{"name":"Boston Clinical Trials  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kairi","family":"M\u00e4gi","sequence":"additional","affiliation":[{"name":"Psychiatric Clinic of Tartu University Hospital  Tartu Estonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahua","family":"She","sequence":"additional","affiliation":[{"name":"AstraZeneca Pharmaceuticals  Wilmington DE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Datto","sequence":"additional","affiliation":[{"name":"AstraZeneca Pharmaceuticals  Wilmington DE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Eriksson","sequence":"additional","affiliation":[{"name":"AstraZeneca Pharmaceuticals R&amp;D S\u00f6dert\u00e4lje  Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,10,16]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.10137"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/10673220303944"},{"key":"e_1_2_8_4_1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, 4th Edition","author":"American Psychiatric Association","year":"1994"},{"key":"e_1_2_8_5_1","unstructured":"AstraZeneca.2012.Seroquel XR (quetiapine fumarate) extended\u2010release tablets \u2013 US prescribing information. (Available from:http:\/\/www1.astrazeneca\u2010us.com\/pi\/seroquelxr.pdf Accessed 26 Apr 2012)."},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145709990423"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/15622970802465807"},{"issue":"2","key":"e_1_2_8_8_1","first-page":"1S","article-title":"Management of anxiety disorders","volume":"51","author":"Canadian Psychiatric Association","year":"2006","journal-title":"Can J Psychiatry"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900026651"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12603-009-0030-0"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.949"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.s.7002.05"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0420f"},{"key":"e_1_2_8_14_1","first-page":"218","volume-title":"ECDEU assessment manual for psychopharmacology publication","author":"Guy W","year":"1976"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n1012"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0603"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1532-5415.2002.50003.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200923020-00002"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32833e34d9"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.janxdis.2008.03.002"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.12.1305"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318224864d"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/026988119801200212"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2008.977"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145709990460"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32834d9f49"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.176.4.363"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/25.4.273"},{"key":"e_1_2_8_31_1","unstructured":"NICE guidelines.2007.Clinical Guideline 22 (amended) Anxiety: management of anxiety (panic disorder with or without agoraphobia and generalised anxiety disorder) in adults in primary secondary and community care. Available from:http:\/\/www.nice.org.uk\/nicemedia\/pdf\/CG022NICEguidelineamended.pdf[Accessed: September 27 2012]."},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050100"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.54.2.145"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(98)00126-7"},{"key":"e_1_2_8_35_1","first-page":"117","volume-title":"Clinical geriatric psychopharmacology","author":"Salzman C","year":"2004"},{"issue":"20","key":"e_1_2_8_36_1","first-page":"22","article-title":"The Mini\u2010International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM\u2010IV and ICD\u201010","volume":"59","author":"Sheehan DV","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6394(2000)11:3<114::AID-DA5>3.0.CO;2-C"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900020307"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1037\/0882-7974.18.3.622"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.10065"},{"issue":"8","key":"e_1_2_8_41_1","first-page":"24","article-title":"Generalized anxiety and depression in primary care: prevalence, recognition, and management","volume":"63","author":"Wittchen HU","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3956(03)00018-9"}],"container-title":["International Journal of Geriatric Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fgps.3867","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/gps.3867","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T05:47:13Z","timestamp":1698644833000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/gps.3867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,16]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.1002\/gps.3867"],"URL":"https:\/\/doi.org\/10.1002\/gps.3867","archive":["Portico"],"relation":{},"ISSN":["0885-6230","1099-1166"],"issn-type":[{"value":"0885-6230","type":"print"},{"value":"1099-1166","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,16]]}}}